• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/7

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

7 Cards in this Set

  • Front
  • Back
Esophageal CA: change with fundus involvement?

Change going higher up in esophagus?

Radiation, chemo + radiation remission?
Can't remove fundus; excludes surgery.

Higher in esophagus = poorer prognosis (can’t replace esophagus).

Rads: 80%; both: 85%
Postop followup procedures for esophageal surgery (2)?

Gastric side effects (3)?
Followup: EGD / CT

Side effects: achlorhydria, B<sub>12</sub> deficiency, early satiety
Esophageal cancer risk factors:

which for adenocarcinoma, which for squamous carcinoma?

Barrett’s esophagus, drinking, GERD, obesity, smoking
Adenocarcinoma: Barrett’s esophagus, GERD, obesity

Squamous carcinoma: drinking, smoking
N1 excludes treatment?
Excludes radiation: lymph nodes are too far for a local radiation dose.
Iron deficiency anemia from perimenopause

If gastric adenocarcinoma found on biopsy, next diagnostic step?

Followup? Supplementation?
(Do MMA as substitute for Schilling test.)

After gastric scope, do a CT to find other lymph node involvement.

Followup: PET/CT fusion (radio F attached to glucose) @ 5 years, consider 10

Provide iv iron, B<sub>12</sub> supplementation.
HER2neu link to GI cancer?
Gastric adenocarcinoma. (Also breast CA, of course.)
Tumor of head of pancreas: best evaluation by?

Tx: Whipple procedure? outcome?

Another option?
ERCP, image-guided needle biopsy (issues: miss area of interest; may not get enough tissue; core biopsy may induce pancreatitis)

Whipple: resect head of pancreas, duodenum/jejunum into stomach, reroute bile duct

Best option: gemcitabine (nucleoside analog)/erlotinib (EGFR inhibitor)